ClinicalTrials.gg
CompletedNCT00550095Updated Feb 23, 2017

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of valsartan in Microalbuminuria and Proteinuria, sponsored by Novartis. Completed at 1 site in Egypt. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
509
Allocation
Not applicable
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Proteinuria by Novartis — 7 open to participants now, 7 under way, 4 of them phase 3. Proteinuria · Novartis.

Started
2007
the only one that year
Phase 4
2 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Proteinuria by Novartis, this one is the only one that started in 2007, is one of 2 in phase 4, and was the 2nd registered.

Proteinuria

329 studies on the registry are indexed under Proteinuria; 44 are open to participants now.

Browse Proteinuria studies →

Open to participants now

7 of the 12 studies in Proteinuria by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 32 Proteinuria studies recruiting now, 12 (38%) set no upper age limit and 16 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Proteinuria by Novartis, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy of the different dosage forms of Valsartan[80, 160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.

03

Conditions studied

  • Microalbuminuria
  • Proteinuria

Browse trials for

Keywords

  • Microalbuminuria/proteinuria
  • hypertensive patients with type 2 diabetes
  • Valsartan
  • microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 35 to 75.
  • Type 2 diabetes mellitus (DM) patients coupled with hypertension [sitting systolic blood pressure (SSBP) 140-179 mm Hg and/or SDBP 90-109 mm Hg].
  • Urinary albumin creatinine Ratio (UACR)) indicating microalbuminuria/proteinuria [30-1000 mg/g or 2.5-25 mg/mmol]
  • (BMI) \<40 kg/m2
  • Patients who will sign an .

Exclusion criteria

Exclusion Criteria

  • Type 1 DM
  • All causes of secondary diabetes mellitus
  • Women of who refuse to use .
  • Pregnant or lactating females.
  • Severe hypertension [SSBP> 180 mmHg, sitting diastolic blood pressure (SDBP) > 110 mmHg ]
  • Patients who are on combo therapy to control BP
  • Patients who are already on Valsartan.
  • to Valsartan.
  • Renal artery stenosis [ unilateral or bilateral]
  • Patients taking β blockers, (Angiotensin Converting Enzyme Inhibitor (ACEI) or spironolactone
  • Heart Failure
  • History of myocardial infarction, Percutaneous Transluminal Coronary Angioplasty(PTCA) or cerebrovascular accident within the preceding 3 months.
  • Creatinine levels > 1.4 mg/dl [ 0.07mmol/l]. Liver enzymes > 2 times (ULN). Diabetic keto-acidosis (DKA) within the last 6 months. Presence of diabetic neuropathy or retinopathy. Diabetic foot complications. Presence of infection at time of screening. Hyperkalemia (serum K+ > 5.5 mmol/L)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
509 participants (actual)

Study arms

  • Experimental
    1

    valsartan

    Drug: valsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.

    Time frame: Week 24

Secondary outcomes

  1. Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80)

    Time frame: Week 24

07

Study locations

1 site
  • Novartis Investigative Site ,
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Oct 26, 2007
Start
Jun 2007
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00550095
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 26, 2007
Start date
Jun 2007
Primary completion
Nov 2009
Completion
Nov 2009
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study chair · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion